The most severe clinical manifestations result from mutations in SLC6A3, SLC6A5, SLCA18, and SLCA19 giving rise to infantile dystonia and parkinsonism (5, –, 7), hyperekplexia (9, –, 11), and Hartnup disease (45, –, 47), respectively. Here, SLC6A5 is linked to Parkinsonism.